A R Nicol|M Eccles - JoVE Visualize

Showing results (121-130 of 292) with videos related to

Pageof 30

Sort By:

Journal of Medical Genetics|September 1, 2010

A novel HER2-positive breast cancer phenotype arising from germline TP53 mutationsJ R F Wilson, A C Bateman, H Hanson, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015

BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significanceD M Eccles, G Mitchell, A N A Monteiro, et al.

Journal of Medical Genetics|June 3, 2004

A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPROD G R Evans, D M Eccles, N Rahman, et al.

Clinical Dysmorphology|April 1, 1995

Craniofacial abnormalities, agenesis of the corpus callosum, polysyndactyly and abnormal skin and gut development--the Curry Jones syndromeI K Temple, D M Eccles, R M Winter, et al.

Environmental Science & Technology|January 21, 2026

Challenging Additivity: Comparing Predicted and Observed AhR Activity of Polycyclic Aromatic Compound (PAC) Mixtures Containing Active and Inactive ConstituentsKristin M Eccles, Kimberly Gaston, Emily M Green, et al.

Journal of Medical Genetics|April 1, 1994

Adenomatous polyposis coli and a cytogenetic deletion of chromosome 5 resulting from a maternal intrachromosomal insertionJ C Barber, K H Ellis, L V Bowles, et al.

British Journal of Cancer|August 1, 1995

Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumoursH Gabra, L Taylor, B B Cohen, et al.

Archives of Disease in Childhood|March 6, 1998

An unusually severe phenotype for familial adenomatous polyposisD M Eccles, P W Lunt, Y Wallis, et al.

Genomics|June 2, 2001

Characterization of the murine Lbx2 promoter, identification of the human homologue, and evaluation as a candidate for Alström syndromeF Chen, G B Collin, K C Liu, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1991

Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activityM E O'Brien, D M Eccles, S G Allen, et al.

Pageof 30

Showing results (121-130 of 292) with videos related to

Sort By:

Pageof 30

Journal of Medical Genetics|September 1, 2010

A novel HER2-positive breast cancer phenotype arising from germline TP53 mutationsJ R F Wilson, A C Bateman, H Hanson, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015

BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significanceD M Eccles, G Mitchell, A N A Monteiro, et al.

Journal of Medical Genetics|June 3, 2004

A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPROD G R Evans, D M Eccles, N Rahman, et al.

Clinical Dysmorphology|April 1, 1995

Craniofacial abnormalities, agenesis of the corpus callosum, polysyndactyly and abnormal skin and gut development--the Curry Jones syndromeI K Temple, D M Eccles, R M Winter, et al.

Environmental Science & Technology|January 21, 2026

Challenging Additivity: Comparing Predicted and Observed AhR Activity of Polycyclic Aromatic Compound (PAC) Mixtures Containing Active and Inactive ConstituentsKristin M Eccles, Kimberly Gaston, Emily M Green, et al.

Journal of Medical Genetics|April 1, 1994

Adenomatous polyposis coli and a cytogenetic deletion of chromosome 5 resulting from a maternal intrachromosomal insertionJ C Barber, K H Ellis, L V Bowles, et al.

British Journal of Cancer|August 1, 1995

Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumoursH Gabra, L Taylor, B B Cohen, et al.

Archives of Disease in Childhood|March 6, 1998

An unusually severe phenotype for familial adenomatous polyposisD M Eccles, P W Lunt, Y Wallis, et al.

Genomics|June 2, 2001

Characterization of the murine Lbx2 promoter, identification of the human homologue, and evaluation as a candidate for Alström syndromeF Chen, G B Collin, K C Liu, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1991

Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activityM E O'Brien, D M Eccles, S G Allen, et al.

Pageof 30